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Abstract
LRSAM1 mutations have been found in recessive and dominant forms of Char-
cot–Marie–Tooth disease. Within one generation of the original Dutch family
in which the dominant LRSAM1 mutation was identified, three of the five
affected family members have developed Parkinson’s disease between ages 50
and 65 years, many years after neuropathy onset. We speculate that this late-
onset parkinsonism is part of the LRSAM1 phenotype, thus associating a hith-
erto peripheral nerve disease with a central nervous system phenotype. How the
mutated Lrsam1 protein, which normally has E3 ubiquitin ligase activity and is
expressed in the nervous system, impacts on substantia nigra neurons is
unclear.
Introduction
The hereditary neuropathies are clinically, but even more
so genetically, a very heterogeneous group of diseases.
Recently, members of our group identified a frameshift
mutation in LRSAM1 as the cause of dominantly inher-
ited, axonal sensorimotor neuropathy in a Dutch family
(Charcot–Marie–Tooth, CMT, type 2P).1 This finding was
confirmed by others,2,3 and another homozygous muta-
tion in this gene was previously found in a recessive
CMT family (AR-CMT2P).4 In the original paper on the
Dutch family, the clinical description incidentally men-
tioned that two of the affected members showed signs of
Parkinson’s disease (PD). This observation was not high-
lighted, and this possible association does not come up
through the usual search engines in the medical literature.
As we have recently seen a third family member with
signs of PD, we believe that this is not just a chance asso-
ciation, and that the LRSAM1 mutation might be related
to the co-occurring PD. Here, we detail the parkinsonian
phenotype of three affected family members.
Case Descriptions
Figure 1 shows the pedigree of the family. Three of the
five affected family members in the second generation
suffer from parkinsonism, on top of the axonal sensori-
motor neuropathy.
Case 1 (2.2)
This man, now 72 years old, diagnosed earlier with CMT2,
was referred to us at 66 years because of reduced right leg
agility since 2 years. He mentioned more difficulties with
walking and festination. The right leg was getting weaker.
He could previously walk with a cane, but now had to use
a stroller. His right more than left leg occasionally glued to
the floor. He mentioned difficulty turning in bed. He
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experienced reduced dexterity on the right with a hand
tremor. Balance was impaired and he had one fall. Smell
was normal. There was mild urinary urgency with erectile
dysfunction since 2 years. Cognition was unchanged.
Upon examination at that time, we saw a masked face,
slightly monotonous speech, jerky pursuit eye movements,
rigidity and bradykinesia of all limbs but more pro-
nounced on the right, dragging of the right leg and a foot
drop on the left, rest and action tremor of the right hand,
weakness and wasting of distal more than proximal leg
muscles, sensory disturbances in a sock-and-glove distri-
bution, and lower limb areflexia. A dopamine transporter
(DaT) SPECT scan (Fig. 1) demonstrated bilaterally
reduced uptake, putamen more than caudate and more
pronounced on the left. He was started on levodopa and
noticed benefit with levodopa/carbidopa CR 125 mg tid
(but no extra improvement with a higher dose).
Case 2 (2.4)
This man, now 68 years old, was seen at the age of
66 years because of functional decline. He was already
carrying the diagnosis of CMT2. Since 1 year, he was feel-
ing more stiff and slow. Increased walking difficulties had
led to wheelchair dependency. He had noticed more diffi-
culty dual tasking and loss of initiative. He mentioned
the presence of a hand tremor, left more than right. There
was hyposmia and some urinary urgency. Upon examina-
tion, we found wasting and weakness of distal more than
proximal leg muscles, and to a lesser extent also of distal
more than proximal arm muscles, combined with are-
flexia and hypesthesia of the hands and anesthesia of both
legs. There was bradykinesia, more pronounced on the
left, and rigidity that was more pronounced on the right
with cogwheeling. MRI showed some focal white matter
Figure 1. The top shows the family pedigree. Squares: males, circles: females. Black filled symbols indicate those affected by Charcot–Marie–
Tooth (CMT). Symbols that are half black and half lined indicate those affected by both CMT and Parkinson’s disease. The bottom shows the
abnormal DaT SPECT scans of the three males with both CMT and Parkinson’s disease. Note the asymmetrically reduced uptake and pattern of
more putamen than caudate involvement.
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hyperintensities and slight cortical atrophy. A DaT scan
demonstrated profoundly reduced basal ganglia uptake
(putamen bilaterally and left caudate; Fig. 1). Levodopa
and later ropinirol were started, with moderate benefit.
An attempt to stop the levodopa led to worsening of
motor signs, which again improved when levodopa was
re-installed (to now 1000 mg per day). The CMT features
continue to dominate the clinical picture and to have the
greatest impact on his level of functioning.
Case 3 (2.5)
The youngest brother, now aged 67 years, was diagnosed
with PD at the age of 52 years, when he was already
known to have CMT2. He had noticed reduced arm
swing, with stiffness and reduced dexterity of his left arm
for about one and a half year. His sense of smell had
diminished. On examination, in addition to the known
CMT stigmata, there was a slightly monotonous speech,
absent arm swing on the left, an action tremor of the left
more than right hand, and left-sided rigidity. He was ini-
tially started on pergolide, but a switch to levodopa with
entacapone provided good relief of his mainly left-sided
parkinsonism. After 4 years of treatment, peak-dose dysk-
inesias developed and he started to freezing and some
falls; he needed a stroller because of this. A DaT scan at
the age of 60 years showed severely reduced uptake in left
more than right putamen, and to a lesser extent in left
more than right caudate (Fig. 1). Examination at the age
of 61 years in an on-phase showed masked face, weak
and monotonous voice, no tremor, mild bradykinesia and
rigidity left more than right, dyskinesias of all extremities
but left more than right, severely impaired walking (with
support) with freezing episodes, and reduced balance.
Over the following years, while being on levodopa and
amantadine, there was progression of dyskinesias, unpre-
dictable on–off fluctuations arose, and a further progres-
sion of gait and balance difficulties, as well as of his lower
limb sensory disturbances, were apparent. He underwent
deep brain stimulation of the subthalamic nucleus at age
64. The procedure was complicated by a subdural hemor-
rhage and he did not gain much benefit over the follow-
ing months. At present, there is severe dysarthria, lateral
flexion of the trunk to the right, severe bradykinesia, no
dyskinesias, and he can only walk with a stroller during
which freezing and poor balance are observed.
Genetic Findings
As described in the original paper,1 all family mem-
bers affected by CMT2, including the three with concomi-
tant PD, were carrying a frameshift mutation
(c.2121_2122insGC; p.Leu708Argfx28) in the LRSAM1
gene. In addition, we excluded mutations in other genes
that are associated with genetic forms of parkinsonism in
subject 2.4 (SNCA, parkin, PINK1, DJ-1, GBA, POLG,
VPS35, DNAJC13, LRRK2, ATXN2, ATXN3, CACNA1A,
TBP, and ATN1). For detailed methodology, see Data S1.
Discussion
We here share the observation that three members from a
CMT2P family with LRSAM1 mutations have developed
dopa-responsive parkinsonism and speculate that parkin-
sonism is part of the LRSAM1 phenotype. The parkinso-
nian features developed at ages 50–65 years, many years
after the onset of peripheral neuropathy, and were asym-
metric. Two patients had reduced smell. All showed an
effect of levodopa, although the actual functional benefit
was modest because of the coexisting neuropathy. One
patient also showed the long-term complications of
dopaminergic treatment. Nuclear imaging proved that the
parkinsonian features were due to degeneration of the
nigrostriatal pathway. Therefore, at the clinical and imag-
ing levels, the parkinsonian component of the phenotype
in these LRSAM1 mutation carriers seems in keeping with
classic PD. We have no neuropathological data to answer
the question of whether there is Lewy body pathology.
The other family members did not show any signs of
PD, but we did not systematically do DaT scanning or
smell testing to look for preclinical nigra degeneration or
premotor signs, respectively.
The combination of parkinsonism and neuropathy has
a differential diagnosis, but we believe that the specific
context of this family rules out most alternative explana-
tions. There is a possibility of a second genetic condition
in the family that explains the parkinsonism. We were
able to exclude mutations in most of the currently known
PARK genes, but a mutation in another gene – yet
unknown to be related to genetic forms of parkinsonism
– remains possible.
Interestingly, there is an older report on seven cases, of
which five were familial, with CMT type 2 and dopa-
mine-responsive parkinsonism that developed years later.5
We have contacted the first author, who indicated that
there was no genetic follow-up and DNA samples were
not available for testing (C. Tranchant, pers. comm.).
LRSAM1 encodes a multifunctional protein and is
expressed in the fetal and adult nervous system.1 Its ubiq-
uitylating capacity was shown to be perturbed as a result
of the Dutch mutation. The only known target for
LRSAM1 ubiquitylation is TSG101, a component of the
ESCRT machinery (endosomal-sorting complex required
for transport). Ubiquitylation has mostly been associated
with protein degradation, however, other nonproteolytic
pathways have been described, such as internalization and
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modulation of protein interactions, cellular localization,
transcription, and signaling. The fate of the ubiquitylated
substrate largely depends on the type of ubiquitin modifi-
cation and other (opposing) factors such as the deubiqui-
tylating enzymes. Little is known about the specificity of
noncanonical polyubiquitylation that LRSAM1 has been
described to favor in vitro. It is interesting to note that
parkin also mediates formation of Lys-27-ubiquitin
chains.6 Mutations in PINK1 and parkin mediate degrada-
tion of mitochondria through mitophagy, and lead to fail-
ure of mitochondrial translocation.7 Recently, LRSAM1
was shown to be crucial for autophagy of intracellular
Salmonella of infected HeLa cells. This raises intriguing
questions regarding the endogenous LRSAM1 targets and
seems to link processes of mitochondrial dynamics and
autophagy. Animal models have proven that LRSAM1
mutations cause neurological disease in mouse and zebra-
fish.1,8 In this respect, it is interesting to note that lr-
sam1/ mice when challenged with acrylamide showed
poor coordination and tremor.8 Additionally, LRSAM1
has been linked to Huntington’s disease (HD), suggesting
that LRSAM1 also plays a role in CNS neurons.9 It is yet
unclear what this role is and how mutations in this gene
lead to substantia nigra pathology.
Further studies are encouraged, such as carefully check-
ing for signs of PD in other LRSAM1 pedigrees, consider-
ing to test for LRSAM1 mutations in patients with this
particular combination, and investigating whether muta-
tions in this gene are involved in genetic forms of parkin-
sonism in the absence of neuropathy.
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